search
Back to results

An Effectiveness and Safety Study of Chinese Herbal Medicine for Functional Constipation

Primary Purpose

Functional Gastrointestinal Disorders, Constipation

Status
Completed
Phase
Phase 2
Locations
China
Study Type
Interventional
Intervention
MaZiRenWan (MZRW)
Placebo
Sponsored by
Hong Kong Baptist University
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Functional Gastrointestinal Disorders focused on measuring Functional Constipation, Chinese Herbal Medicine, MaZiRenWan, Hemp Seed Pill, Traditional Chinese Medicine, Herbal Medicine

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • Meet of Rome III diagnostic criteria of functional constipation
  • Meet the diagnosis of Excessive Constipation according to the TCM theory
  • Age of 18 to 65 years (inclusive)
  • Complete spontaneous bowel movement (CSBM)≦2times/wk
  • Severity of constipation≧4pts (7 pts scale from 0 to 6pts) and the overall scoring of constipation-related symptoms≧8pts (6items in 7pts scale) for self symptom assessment in the run-in period
  • Normal colonic evaluation (colonoscopy or barium enema) within 5 years
  • Normal liver and renal function in blood test within 3 months

Exclusion Criteria:

  • Drug-induced constipation
  • Secondary causes of constipation (i.e. medical history of diabetes mellitus and thyroid disease)
  • Abdominal surgery (i.e. Caesarean operation)
  • Severe disease (i.e. cancer and acute present asthma)
  • Allergy to CHM (i.e. G6PD deficiency)
  • Pregnancy or breast-feeding
  • Psychiatric or addictive disorders

Sites / Locations

  • Hong Kong Baptist University Mr. & Mrs. Chan Hon Yin Chinese Medicine Specialty Clinic and Good Clinical Practice Centre

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Placebo Comparator

Arm Label

MaZiRenWan (MZRW)

Placebo

Arm Description

MZRW granule, 7.5g/sachet

Placebo granule, 7.5g/sachet

Outcomes

Primary Outcome Measures

Responder of Complete Spontaneous Bowel Movement (CSBM)
Patients with a mean increase of ≧1 complete spontaneous bowel movement(CSBM)/wk compared with the baseline(wk1-2) will be defined as responders. CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.

Secondary Outcome Measures

Responder of Complete Spontaneous Bowel Movement (CSBM)
Participants with a mean increase of complete spontaneous bowel movement (CSBM)>=1 movement per week compared with the last 14 days of the run-in period were defined as responders. CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.
Bowel Movement
Complete Spontaneous Bowel Movement (CSBM)
Changes on Individual Symptom Scores
It was a 7-point ordinal scale from 0=not at all to 6=very severe.
Global Symptoms Improvement
Participants were asked to rate their impression of change in constipation by comparing with their baseline (Wk2) at the visits during the treatment (Wk6), end of treatment (Wk10) and end of follow-up (Wk18) with scores from 0 to 6 represented markedly worse or better respectively. The response categories were collapsed to simply "improved" for score 4 to 6, "same" for score 3 or "worse" for score 0 to 2.
Success of Blinding
The success of blinding was evaluated for both investigator and patients as to whether MZRW or placebo had been taken.
Blood Urea Level
Blood Creatinine Level
Serum Glutamic Pyruvic Transaminase(SGPT) Level
Serum Glutamic Oxaloacetic Transaminase (SGOT)

Full Information

First Posted
August 25, 2008
Last Updated
May 23, 2016
Sponsor
Hong Kong Baptist University
Collaborators
Food and Health Bureau, Hong Kong, PuraPharm International (H.K.) Ltd
search

1. Study Identification

Unique Protocol Identification Number
NCT00741936
Brief Title
An Effectiveness and Safety Study of Chinese Herbal Medicine for Functional Constipation
Official Title
Chinese Herbal Medicine for Functional Constipation: A Randomized, Double-blind, Placebo Controlled Trial
Study Type
Interventional

2. Study Status

Record Verification Date
March 2015
Overall Recruitment Status
Completed
Study Start Date
July 2008 (undefined)
Primary Completion Date
November 2009 (Actual)
Study Completion Date
December 2009 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Hong Kong Baptist University
Collaborators
Food and Health Bureau, Hong Kong, PuraPharm International (H.K.) Ltd

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Functional constipation (FC) is a common complaint in clinical practice, but treatment for this condition in conventional medicine is suboptimal. Complementary and alternative medicines, especially Chinese herbal medicine (CHM) are used frequently by patients, however, there is little research evidence about these commonly used CHM. The purpose of the study is evaluate the efficacy and safety of an ancient CHM formula, MaZiRenWan (MZRW), by comparing with placebo.
Detailed Description
Constipation is a common gastrointestinal complaint in clinical practice, which affects in estimated 12%-19% of American, 14% of Asian, and up to 27% of the population depending on demographic factor, sampling, and definition. With the unsatisfactory response to current symptomatic treatments, many patients seek help from traditional Chinese medicine (TCM), mostly by taking Chinese herbal medicine (CHM). According to the TCM theory, constipation can be broadly divided into two types, excessive and deficient, based on the underlying aetiology. The former is characterized by the presence of Heat or pathological accumulation of Qi. Heat causes constipation by drying the Intestines and the stool. Patients present with hard, dry, pellet like stool, red complexion, dry mouth or halitosis, red tongue with a dry yellow coat, and slippery and rapid pulse. Qi stagnation causes constipation by disrupting the normal movement and descent of Stomach and Intestinal Qi. Patients present difficulty in passing stools, feelings of incomplete evacuation, abdominal distension or pain, frequent belching and flatulence, tongue with thin coat and wiry pulse. The latter, deficient constipation, is delineated as the dryness from insufficient fluid lubrication in the form of blood or lack of propulsion power from the deficiency of Qi or Yang. Besides, the treatment approaches vary from syndrome to syndrome. The formula of MaZiRenWan (MZRW) composed of six Chinese herbs is firstly recorded in a TCM classic, Discussion of Cold-induced Disorders (Shang Han Lun), and it has been commonly used for constipation in excessive pattern throughout Asia since the Han Dynasty (A.D. 200). By combining the actions of these herbs, MZRW can moisten the Intestines, drain heat, promote the movement of Qi and unblock the bowel. Although previous studies show that MZRW has purgative and laxative effects and may be useful for functional constipation (FC), there are significant methodological weaknesses. Furthermore, the dose of CHM intervention being investigated from the first randomized controlled trial (RCT) published in 1983 is always based on the practitioner's experience, TCM literatures, or experts' comments, but not the results from stringent clinical trials, such as dose determination study. Therefore, the evidence produced will be attenuated or even misleading if improper dose is taken. In the present study, the efficacy and safety of MZRW in optimal dosage were justified by comparing with placebo under strict clinical trial design.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Functional Gastrointestinal Disorders, Constipation
Keywords
Functional Constipation, Chinese Herbal Medicine, MaZiRenWan, Hemp Seed Pill, Traditional Chinese Medicine, Herbal Medicine

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 2
Interventional Study Model
Parallel Assignment
Masking
ParticipantInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
120 (Actual)

8. Arms, Groups, and Interventions

Arm Title
MaZiRenWan (MZRW)
Arm Type
Experimental
Arm Description
MZRW granule, 7.5g/sachet
Arm Title
Placebo
Arm Type
Placebo Comparator
Arm Description
Placebo granule, 7.5g/sachet
Intervention Type
Drug
Intervention Name(s)
MaZiRenWan (MZRW)
Other Intervention Name(s)
Hemp Seed Pill
Intervention Description
MZRW granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
Intervention Type
Drug
Intervention Name(s)
Placebo
Other Intervention Name(s)
MZRW Placebo
Intervention Description
Placebo granule dissolved in 150ml hot water (oral), 7.5g/sachet, twice daily
Primary Outcome Measure Information:
Title
Responder of Complete Spontaneous Bowel Movement (CSBM)
Description
Patients with a mean increase of ≧1 complete spontaneous bowel movement(CSBM)/wk compared with the baseline(wk1-2) will be defined as responders. CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.
Time Frame
End of treatment (wk10)
Secondary Outcome Measure Information:
Title
Responder of Complete Spontaneous Bowel Movement (CSBM)
Description
Participants with a mean increase of complete spontaneous bowel movement (CSBM)>=1 movement per week compared with the last 14 days of the run-in period were defined as responders. CSBM referred to the feeling that defecation led to complete passage of stool rather than partial or incomplete evacuation without the use of any laxative or enema within 24 hours.
Time Frame
End of follow up (wk18)
Title
Bowel Movement
Time Frame
Baseline(Wk1&2), Within treatment(Wk3-10) & Within follow-up(Wk11-18)
Title
Complete Spontaneous Bowel Movement (CSBM)
Time Frame
Baseline(Wk1&2), Within treatment(Wk3-10), Within follow-up(Wk11-18)
Title
Changes on Individual Symptom Scores
Description
It was a 7-point ordinal scale from 0=not at all to 6=very severe.
Time Frame
Baseline(Wk2), Within treatment(Wk6), End of treatment(Wk10) & End of follow-up(Wk18)
Title
Global Symptoms Improvement
Description
Participants were asked to rate their impression of change in constipation by comparing with their baseline (Wk2) at the visits during the treatment (Wk6), end of treatment (Wk10) and end of follow-up (Wk18) with scores from 0 to 6 represented markedly worse or better respectively. The response categories were collapsed to simply "improved" for score 4 to 6, "same" for score 3 or "worse" for score 0 to 2.
Time Frame
Wk 6, 10 & wk 18
Title
Success of Blinding
Description
The success of blinding was evaluated for both investigator and patients as to whether MZRW or placebo had been taken.
Time Frame
End of follow-up (Wk18)
Title
Blood Urea Level
Time Frame
Pre-treatment (Wk2) & Post-treatment (Wk10)
Title
Blood Creatinine Level
Time Frame
Pre-treatment (Wk2) & Post-treatment (Wk10)
Title
Serum Glutamic Pyruvic Transaminase(SGPT) Level
Time Frame
Pre-treatment (Wk2) & Post-treatment (Wk10)
Title
Serum Glutamic Oxaloacetic Transaminase (SGOT)
Time Frame
Pre-treatment (Wk2) & Post-treatment (Wk10)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Meet of Rome III diagnostic criteria of functional constipation Meet the diagnosis of Excessive Constipation according to the TCM theory Age of 18 to 65 years (inclusive) Complete spontaneous bowel movement (CSBM)≦2times/wk Severity of constipation≧4pts (7 pts scale from 0 to 6pts) and the overall scoring of constipation-related symptoms≧8pts (6items in 7pts scale) for self symptom assessment in the run-in period Normal colonic evaluation (colonoscopy or barium enema) within 5 years Normal liver and renal function in blood test within 3 months Exclusion Criteria: Drug-induced constipation Secondary causes of constipation (i.e. medical history of diabetes mellitus and thyroid disease) Abdominal surgery (i.e. Caesarean operation) Severe disease (i.e. cancer and acute present asthma) Allergy to CHM (i.e. G6PD deficiency) Pregnancy or breast-feeding Psychiatric or addictive disorders
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Zhao-xiang Bian, PhD
Organizational Affiliation
Hong Kong Baptist University
Official's Role
Principal Investigator
Facility Information:
Facility Name
Hong Kong Baptist University Mr. & Mrs. Chan Hon Yin Chinese Medicine Specialty Clinic and Good Clinical Practice Centre
City
Hong Kong
Country
China

12. IPD Sharing Statement

Citations:
PubMed Identifier
21045817
Citation
Cheng CW, Bian ZX, Zhu LX, Wu JC, Sung JJ. Efficacy of a Chinese herbal proprietary medicine (Hemp Seed Pill) for functional constipation. Am J Gastroenterol. 2011 Jan;106(1):120-9. doi: 10.1038/ajg.2010.305. Epub 2010 Nov 2.
Results Reference
result
Links:
URL
http://www.ncbi.nlm.nih.gov/pubmed/21045817
Description
Abstract

Learn more about this trial

An Effectiveness and Safety Study of Chinese Herbal Medicine for Functional Constipation

We'll reach out to this number within 24 hrs